finance.yahoo.com

Jim Cramer favors Eli Lilly for strong growth over J&J and Pfizer

Johnson & Johnson logoJohnson & Johnson
Sig1.35Sen+2.25Env0.00Soc0.00Gov0.00
Eli Lilly logoEli Lilly
Sig1.65Sen+2.85Env0.00Soc0.00Gov0.00
Pfizer logoPfizer
Sig1.28Sen-0.78Env0.00Soc0.00Gov0.00

A caller asked whether to rotate from artificial intelligence stocks into Eli Lilly instead of Johnson & Johnson or Cardinal Health. Eli Lilly is described as having the strongest growth profile, with investors paying more for its faster growth. Fiscal 2026 revenue rose 14% to $254.2 billion and non-GAAP diluted EPS rose 37% to $11.26. Continued growth from Mounjaro and Zepbound is key, leaving the stock exposed to demand slowdowns, pricing pressure, and stronger competition.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro